Department of Medical Microbiology & Immunology, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB T6G 2E1, Canada.
Department of Physics, Faculty of Science, University of Alberta, Edmonton, AB T6G 2E1, Canada.
Cells. 2022 Aug 31;11(17):2712. doi: 10.3390/cells11172712.
The effects of electric fields (EFs) on various cell types have been thoroughly studied, and exhibit a well-known regulatory effect on cell processes, implicating their usage in several medical applications. While the specific effect exerted on cells is highly parameter-dependent, the majority of past research has focused primarily on low-frequency alternating fields (<1 kHz) and high-frequency fields (in the order of MHz). However, in recent years, low-intensity (1-3 V/cm) alternating EFs with intermediate frequencies (100-500 kHz) have been of topical interest as clinical treatments for cancerous tumours through their disruption of cell division and the mitotic spindle, which can lead to cell death. These aptly named tumour-treating fields (TTFields) have been approved by the FDA as a treatment modality for several cancers, such as malignant pleural mesothelioma and glioblastoma multiforme, demonstrating remarkable efficacy and a high safety profile. In this work, we report the results of in vitro experiments with HeLa and MCF-10A cells exposed to TTFields for 18 h, imaged in real time using live-cell imaging. Both studied cell lines were exposed to 100 kHz TTFields with a 1-1 duty cycle, which resulted in significant mitotic and cytokinetic arrest. In the experiments with HeLa cells, the effects of the TTFields' frequency (100 kHz vs. 200 kHz) and duty cycle (1-1 vs. 1-0) were also investigated. Notably, the anti-mitotic effect was stronger in the HeLa cells treated with 100 kHz TTFields. Additionally, it was found that single and two-directional TTFields (oriented orthogonally) exhibit a similar inhibitory effect on HeLa cell division. These results provide real-time evidence of the profound ability of TTFields to hinder the process of cell division by significantly delaying both the mitosis and cytokinesis phases of the cell cycle.
电场(EFs)对各种细胞类型的影响已经得到了深入研究,并对细胞过程表现出了显著的调节作用,这暗示着它们在许多医学应用中的使用。虽然对细胞施加的具体影响高度依赖于参数,但过去的大多数研究主要集中在低频交流场(<1 kHz)和高频场(MHz 量级)上。然而,近年来,低强度(1-3 V/cm)、中频(100-500 kHz)的交流 EF 作为癌症肿瘤的临床治疗方法引起了人们的关注,因为它们可以通过干扰细胞分裂和有丝分裂纺锤体来导致细胞死亡。这些电场被恰当地命名为肿瘤治疗电场(TTFields),已经被 FDA 批准为几种癌症的治疗方法,如恶性胸膜间皮瘤和多形性胶质母细胞瘤,显示出显著的疗效和高安全性。在这项工作中,我们报告了用 HeLa 和 MCF-10A 细胞进行的体外实验结果,这些细胞在实时活细胞成像中暴露于 TTFields 18 小时。两种研究细胞系都暴露于 100 kHz 的 TTFields 中,占空比为 1-1,这导致了明显的有丝分裂和胞质分裂停滞。在 HeLa 细胞的实验中,还研究了 TTFields 的频率(100 kHz 与 200 kHz)和占空比(1-1 与 1-0)的影响。值得注意的是,用 100 kHz TTFields 处理的 HeLa 细胞中的抗有丝分裂效应更强。此外,还发现单方向和双方向 TTFields(正交取向)对 HeLa 细胞分裂具有相似的抑制作用。这些结果提供了实时证据,证明 TTFields 具有显著的能力,可以通过显著延迟细胞周期的有丝分裂和胞质分裂阶段来阻碍细胞分裂过程。